SEARCH

SEARCH BY CITATION

References

  • 1
    Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703712.
  • 2
    Hunt SA, Abraham WT, Chin MH, et al.; American College of Cardiology Foundation. American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1e90.
  • 3
    Kocher RP, Adashi EY. Hospital readmissions and the affordable care act: paying for coordinated quality care. JAMA. 2011;306:17941795.
  • 4
    Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990;38:12905.
  • 5
    Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:12131214.
  • 6
    CHF readmissions decline as med needs addressed. Hosp Peer Rev. 2003;28:9798.
  • 7
    Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167:14931502.
  • 8
    Urbaniak GC, Plous S. Research Randomizer (Version 3.0) [Computer software]. Available at: http://www.randomizer.org
  • 9
    White M, Desai RV, Guichard JL, et al. Bucindolol, Systolic Blood Pressure, and Outcomes in Systolic Heart Failure: a prespecified post hoc analysis of BEST. Can J Cardiol. 2012;28:354359.
  • 10
    Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:21942199.
  • 11
    Jost A, Rauch B, Hochadel M, et al. Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study. Eur Heart J. 2005;26:26892697.
  • 12
    The Cardiac Insufficiency Bisoprolol Study II (CIBISII): a randomised trial. Lancet. 1999;353:913.
  • 13
    Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. Arch Intern Med. 1997;157:11031108.
  • 14
    Fu M, Zhou J, Sun A, et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction—a meta analysis of 7 prospective clinical studies. Int J Cardiol. 2012;155:3338.
  • 15
    McKelvie RS. The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Rev Cardiovasc Ther. 2009;7:916.
  • 16
    Komukai K, Ogawa T, Yagi H, et al. Decreased renal function as an independent predictor of re-hospitalization for congestive heart failure. Circ J. 2008;72:11521157.
  • 17
    Hallerbach M, Francoeur A, Pomerantz SC, et al. Patterns and predictors of early hospital readmission in patients with congestive heart failure. Am J Med Qual. 2008;23:1823.
  • 18
    Chae CU, Albert CM, Glynn RJ, et al. Mild renal insufficiency and risk of congestive heart failure in men and women > or =70 years of age. Am J Cardiol. 2003;92:682686.
  • 19
    Risler T, Schwab A, Kramer B, et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology. 1994;84(Suppl 2):155161.
  • 20
    Philbin EF, Santella RN, Rocco TA Jr. Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. J Am Geriatr Soc. 1999;47:302308.
  • 21
    Steiner JF, Robbins LJ, Hammermeister KE, et al. Incidence of digoxin toxicity in outpatients. West J Med. 1994;161:474478.
  • 22
    Chen J, Normand SL, Wang Y, et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA. 2011;306:16691678.
  • 23
    Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA. 2010;303:21412147.
  • 24
    Ross JS, Chen J, Lin Z, et al. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail. 2010;3:97103.
  • 25
    Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001–2005. Arch Intern Med. 2008;168:24812488.
  • 26
    Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol. 2002;39:8389.
  • 27
    Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291:13581367.
  • 28
    Koelling TM, Johnson ML, Cody RJ, et al. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation. 2005;111:179185.
  • 29
    Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933944.
  • 30
    Norton C, Georgiopoulou VV, Kalogeropoulos AP, et al. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis. 2011;54:7885.
  • 31
    Rogers JG, Bostic RR, Tong KB, et al. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail. 2012;5:1016.